Introduction
NSCLC, lung cancers, cancer death
LUNG CANCERS, NSCLC, NON-SMALL CELL LUNG CANCER
Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancers and is the leading cause of cancer death worldwide (Though neoadjuvant immunochemotherapy has greatly succeeded at treating NSCLC, the MPR% of immunochemotherapy is still approximately 36%, which is relatively low (Medical imaging, such as computed tomography (CT), plays a vital role in the diagnosis, evaluation, and treatment monitoring of NSCLC (The present study aimed to develop and validate a radiomics-based model that can efficiently predict MPR for potentially resectable NSCLC treated with neoadjuvant immunochemotherapy. We also explored the integration of CT-based radiomics and clinical data into a multidimensional nomogram to predict MPR.